Glenmark Life Sciences Limited
NSE: GLS BSE: GLS
NSE
1,086.00
1.65 (0.15%)
Prev Close
1084.35
Open Price
1076.45
Volume
130,938
Today Low / High
1056.8 / 1095
52 WK Low / High
676.5 / 1335.1
Range
1,032 - 1,140
BSE
1,085.80
0.00 (0.00%)
Prev Close
1085.8
Open Price
1098
Volume
11,298
Today Low / High
1059.05 / 1098
52 WK Low / High
666.05 / 1335
Range
1,032 - 1,140
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1086 (target range: 1,032 - 1,140), reflecting a change of 1.65 (0.1522%). On the BSE, it is listed at 1085.8 (target range: 1,032 - 1,140), showing a change of 0 (0%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
No data available
Glenmark Life Sciences Limited Graph
Glenmark Life Sciences Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Glenmark Life Sciences Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,086.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,085.80 | 1,096.66 | 986.99 - 1,206.32 |
| 1,107.52 | 886.01 - 1,329.02 | ||
| 1,118.37 | 782.86 - 1,453.89 | ||
| Bearish Scenario | 1,085.80 | 1,074.94 | 967.45 - 1,182.44 |
| 1,064.08 | 851.27 - 1,276.90 | ||
| 1,053.23 | 737.26 - 1,369.19 |
Overview of Glenmark Life Sciences Limited
ISIN
INE03Q201024
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
125,749
Market Cap
133,070,838,000
Last Dividend
43.5
Official Website
IPO Date
2021-08-06
DCF Diff
-60.75
DCF
1,147
Financial Ratios Every Investor Needs
Stock Dividend of GLS
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2023-10-17 | October 17, 23 | 22.5 | 22.5 | 2023-10-17 | 2023-11-08 | |
| 2023-03-24 | March 24, 23 | 21 | 21 | 2023-03-24 | 2023-03-29 | |
| 2022-09-15 | September 15, 22 | 10.5 | 10.5 | 2022-09-16 | 2022-10-26 | |
| 2021-11-22 | November 22, 21 | 10.5 | 10.5 | 2021-11-23 | 2021-12-10 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 2,283.21 Cr | 1,039.92 Cr | 1,243.30 Cr | 0.5450 | 75.30 Cr | 258.54 Cr | 897.92 Cr | 470.89 Cr | 38.43 | 686.29 Cr | 0.2062 |
| 2023-03-31 | 2,161.22 Cr | 1,014.09 Cr | 1,147.13 Cr | 0.5308 | 65.18 Cr | 9.15 Cr | 600.76 Cr | 466.96 Cr | 38.11 | 671.25 Cr | 0.2161 |
| 2022-03-31 | 2,123.21 Cr | 1,042.89 Cr | 1,080.33 Cr | 0.5090 | 57.20 Cr | 8.09 Cr | 578.93 Cr | 418.72 Cr | 35.63 | 630.76 Cr | 0.1972 |
| 2021-03-31 | 1,885.17 Cr | 905.50 Cr | 979.67 Cr | 0.5197 | 0.29 Cr | 7.42 Cr | 561.72 Cr | 351.58 Cr | 32.61 | 591.89 Cr | 0.1865 |
| 2020-03-31 | 1,537.31 Cr | 690.46 Cr | 846.86 Cr | 0.5509 | 40.03 Cr | 7.15 Cr | 443.82 Cr | 313.10 Cr | 29.04 | 483.95 Cr | 0.2037 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 301.41 Cr | 2,850.41 Cr | 518.09 Cr | 2,332.3220 Cr | 17.15 Cr | -284.27 Cr | 666.59 Cr | 896.20 Cr | 0.00 Cr | 0.00 Cr | 0.08 Cr | 438.7730 Cr |
| 2023-03-31 | 283.82 Cr | 2,702.15 Cr | 563.94 Cr | 2,138.2070 Cr | 19.36 Cr | -264.47 Cr | 604.17 Cr | 824.24 Cr | 75.91 Cr | -42.43 Cr | 0.08 Cr | 504.4140 Cr |
| 2022-03-31 | 512.16 Cr | 2,471.01 Cr | 416.70 Cr | 2,054.3120 Cr | 2.88 Cr | -509.27 Cr | 516.24 Cr | 676.34 Cr | 54.51 Cr | -31.50 Cr | 0.08 Cr | 383.9960 Cr |
| 2021-03-31 | 115.60 Cr | 1,997.08 Cr | 1,244.33 Cr | 752.7470 Cr | 932.87 Cr | 817.27 Cr | 513.42 Cr | 578.99 Cr | 7.29 Cr | 0.00 Cr | 0.08 Cr | 1,221.4400 Cr |
| 2020-03-31 | 10.00 Cr | 1,725.60 Cr | 1,323.91 Cr | 401.6920 Cr | 0.02 Cr | -9.98 Cr | 412.78 Cr | 549.81 Cr | -2.42 Cr | 0.00 Cr | 0.08 Cr | 1,307.4640 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 413.5150 Cr | -116.4830 Cr | -279.4410 Cr | 284.5460 Cr | 17.5910 Cr | 301.4140 Cr | -128.9690 Cr | 631.2900 Cr | -2.2090 Cr | -275.6860 Cr | -82.6260 Cr |
| 2023-03-31 | 313.4040 Cr | -154.1450 Cr | -387.5930 Cr | 143.2080 Cr | -228.3340 Cr | 283.8230 Cr | -170.1960 Cr | 628.6090 Cr | -1.1280 Cr | -385.9180 Cr | -87.9270 Cr |
| 2022-03-31 | 597.5850 Cr | -122.2280 Cr | -78.7960 Cr | 465.4130 Cr | 396.5610 Cr | 512.1570 Cr | -132.1720 Cr | 564.9250 Cr | -1.3650 Cr | -128.6540 Cr | -2.8230 Cr |
| 2021-03-31 | 388.1130 Cr | -68.7340 Cr | -213.7810 Cr | 320.1200 Cr | 105.5980 Cr | 115.5960 Cr | -67.9930 Cr | 470.9440 Cr | 0.0000 Cr | 0.0000 Cr | -100.6460 Cr |
| 2020-03-31 | 195.0070 Cr | -50.5180 Cr | -136.5520 Cr | 143.8410 Cr | 7.9370 Cr | 9.9980 Cr | -51.1660 Cr | 421.0670 Cr | 0.0000 Cr | 0.0000 Cr | -11.9320 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 506.88 Cr | 302.73 Cr | 204.15 Cr | 0.4030 | 119.27 Cr | 95.32 Cr | 7.78 | 142.89 Cr | 0.1880 |
| 2024-06-30 | 588.62 Cr | 359.02 Cr | 229.60 Cr | 0.3900 | 145.10 Cr | 111.48 Cr | 9.10 | 159.49 Cr | 0.1894 |
| 2024-03-31 | 536.60 Cr | 238.70 Cr | 297.90 Cr | 0.5550 | 130.04 Cr | 97.94 Cr | 7.99 | 144.58 Cr | 0.1825 |
| 2023-12-31 | 572.80 Cr | 242.19 Cr | 330.61 Cr | 0.5770 | 161.07 Cr | 118.77 Cr | 9.69 | 174.25 Cr | 0.2073 |
| 2023-09-30 | 595.36 Cr | 273.08 Cr | 322.28 Cr | 0.5410 | 159.32 Cr | 118.74 Cr | 9.69 | 172.45 Cr | 0.1994 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 446.12 Cr | 84.09 Cr | 530.20 Cr | 775.13 Cr | 689.20 Cr | 2,096.06 Cr | 945.12 Cr | 3,084.86 Cr | 546.38 Cr |
| 2024-06-30 | -301.59 Cr | 603.19 Cr | 301.59 Cr | 0.00 Cr | 0.00 Cr | 301.59 Cr | 0.00 Cr | 0.00 Cr | -2,332.32 Cr |
| 2024-03-31 | 301.41 Cr | 90.55 Cr | 391.96 Cr | 765.43 Cr | 666.59 Cr | 1,916.00 Cr | 896.20 Cr | 2,850.41 Cr | 518.09 Cr |
| 2023-12-31 | -443.07 Cr | 886.14 Cr | 443.07 Cr | 0.00 Cr | 0.00 Cr | 443.07 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 442.95 Cr | 71.90 Cr | 514.85 Cr | 807.46 Cr | 669.51 Cr | 2,076.68 Cr | 843.80 Cr | 2,952.98 Cr | 561.24 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 111.48 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 97.94 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 118.77 Cr | 26.35 Cr | 0.00 Cr | 0.00 Cr | 26.35 Cr | 469.43 Cr | 443.07 Cr | 0.00 Cr | 26.35 Cr |
| 2023-09-30 | 118.74 Cr | 26.26 Cr | 0.00 Cr | 0.00 Cr | 26.26 Cr | 443.07 Cr | 416.81 Cr | 0.00 Cr | 26.26 Cr |
| 2023-06-30 | 135.45 Cr | 25.22 Cr | 0.00 Cr | 0.00 Cr | 25.22 Cr | 334.62 Cr | 309.40 Cr | 0.00 Cr | 25.22 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,497,390,360.00 | ₹1,539,404.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,891.50 | ₹1,564,008,080,155.00 | ₹717,304.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.60 | ₹1,101,504,496,478.00 | ₹168,941.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.40 | ₹1,067,918,241,168.00 | ₹342,053.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,177.40 | ₹980,907,622,968.00 | ₹1,938,682.00 |
| Lupin Limited | LUPIN | ₹2,009.20 | ₹917,330,458,276.00 | ₹966,589.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹845.35 | ₹850,616,530,500.00 | ₹1,860,605.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,201.20 | ₹697,658,929,968.00 | ₹653,310.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,000.40 | ₹597,872,826,000.00 | ₹97,948.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,368.80 | ₹386,259,126,032.00 | ₹2,163,260.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,423.80 | ₹361,224,068,436.00 | ₹163,712.00 |
| Laurus Labs Limited | LAURUSLABS | ₹640.35 | ₹345,310,338,375.00 | ₹1,671,228.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,679.20 | ₹334,664,498,320.00 | ₹44,703.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,202.20 | ₹306,037,994,912.00 | ₹330,131.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.70 | ₹258,221,804,814.00 | ₹100,079.00 |
| Piramal Enterprises Limited | PEL | ₹1,039.85 | ₹234,462,986,345.00 | ₹552,041.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,401.40 | ₹227,698,028,558.00 | ₹264,593.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,727.50 | ₹218,187,500,000.00 | ₹13,476.00 |
| Eris Lifesciences Limited | ERIS | ₹1,382.90 | ₹188,299,218,053.00 | ₹81,150.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,136.00 | ₹168,533,566,400.00 | ₹53,273.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹849.65 | ₹167,009,863,405.00 | ₹223,768.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹829.80 | ₹148,625,361,828.00 | ₹383,129.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹915.95 | ₹145,893,560,183.00 | ₹228,298.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,906.70 | ₹144,931,500,763.00 | ₹146,966.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹480.20 | ₹116,469,494,344.00 | ₹1,207,487.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,223.50 | ₹86,706,866,654.00 | ₹3,571.00 |
| FDC Limited | FDC | ₹430.60 | ₹70,106,024,754.00 | ₹67,489.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹712.85 | ₹64,608,888,867.00 | ₹374,808.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹658.10 | ₹64,356,197,871.00 | ₹163,074.00 |
| Strides Pharma Science Limited | STAR | ₹640.75 | ₹59,053,256,433.00 | ₹243,236.00 |
| Innova Captab Limited | INNOVACAP | ₹915.85 | ₹52,409,452,141.00 | ₹37,786.00 |
| Hikal Limited | HIKAL | ₹423.80 | ₹52,254,857,850.00 | ₹371,223.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.84 | ₹49,599,942,480.00 | ₹505,473.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹633.90 | ₹44,630,236,620.00 | ₹75,809.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹799.75 | ₹40,562,604,224.00 | ₹101,985.00 |
| Sequent Scientific Limited | SEQUENT | ₹148.17 | ₹37,087,247,340.00 | ₹527,793.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,179.20 | ₹36,041,821,488.00 | ₹10,217.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,098,650.00 | ₹40,163.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹361.65 | ₹33,007,795,500.00 | ₹101,872.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.91 | ₹29,540,183,967.00 | ₹4,747,370.00 |
| Suven Life Sciences Limited | SUVEN | ₹127.13 | ₹27,723,712,024.00 | ₹173,057.00 |
| Alembic Limited | ALEMBICLTD | ₹105.35 | ₹27,051,965,791.00 | ₹436,085.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹520.70 | ₹25,021,207,514.00 | ₹37,558.00 |
Key Executives
Vice President & Head of Corporate Quality
Mr. Navin Kumar Agrawal
Gender: male
Year Born:
Senior Vice President & Head of Human Resources
Mr. Sumantra Mitra
Gender: male
Year Born:
Company Secretary & Compliance Officer
Mr. Rudalf Corriea
Gender: male
Year Born:
General Manager of Corporate Communications
Soumi Rao
Gender: Not Specified
Year Born:
Group Vice President, Head of Technical Operations & Whole Time Director
Mr. Vinod Naik
Gender: male
Year Born:
Chief Executive Officer, MD & Director
Dr. Yasir Yusufali Rawjee Ph.D.
Gender: Not Specified
Year Born: 1965
Senior Vice President & Head of Regulatory Affairs
Mr. Mathew George
Gender: male
Year Born:
Senior Vice President & Chief Financial Officer
Mr. Tushar P. Mistry
Gender: male
Year Born:
FAQs about Glenmark Life Sciences Limited
Who is the CEO of the company?
The CEO is Dr. Yasir Yusufali Rawjee Ph.D..
What is the current market price of the stock?
The current price is ₹1,086.00.
What is the 52-week price range?
The range is ₹676.5-1335.1.
What is the market capitalization of the company?
The market capitalization is ₹13,307.08 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 31.42.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Glenmark Life Sciences Limited (ISIN: INE03Q201024) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹13,307.08 crores and an average daily volume of 125,749 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹43.5.